Group O plasma as a media supplement for CAR-T cells and other adoptive T-cell therapies.

Randin C NelsonVicki FellowesPing JinHui LiuSteven L HighfillJiaqiang RenJames SzymanskiWilly Albert FlegelDavid F Stroncek

Published in: Transfusion (2020)

This study suggests that ABO incompatible plasma may be used as a media supplement when culturing cell types that do not express ABO antigens-such as lymphocytes for CAR-T or other ACT. The presence of contaminating RBCs in culture was disadvantageous independent of isoagglutinin titer.

Keyphrases

cell therapy
induced apoptosis
cell cycle arrest
stem cells
peripheral blood
dendritic cells
cell death